Elanco Animal Health (NYSE:ELAN) Price Target Raised to $16.00 at Stifel Nicolaus

Elanco Animal Health (NYSE:ELAN) had its price objective increased by research analysts at Stifel Nicolaus from $15.00 to $16.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 22.92% from the company’s current price.

ELAN has been the topic of a number of other reports. Barclays lowered their target price on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. UBS Group lowered their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Morgan Stanley lowered their price objective on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 26th. Finally, Piper Sandler cut their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday, March 6th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health currently has a consensus rating of “Hold” and a consensus price target of $15.17.

Elanco Animal Health Stock Up 0.8%

Shares of ELAN traded up $0.10 during trading hours on Monday, hitting $13.02. The stock had a trading volume of 572,252 shares, compared to its average volume of 5,025,994. The firm has a 50 day simple moving average of $10.11 and a 200-day simple moving average of $11.43. The firm has a market capitalization of $6.46 billion, a P/E ratio of 32.57, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health has a 1-year low of $8.02 and a 1-year high of $18.80.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the prior year, the company posted $0.34 earnings per share. The firm’s revenue for the quarter was down 1.0% on a year-over-year basis. Sell-side analysts predict that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Insider Activity

In other news, Director Lawrence Erik Kurzius acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The stock was bought at an average cost of $10.90 per share, for a total transaction of $109,000.00. Following the acquisition, the director now directly owns 101,459 shares in the company, valued at approximately $1,105,903.10. The trade was a 10.93% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 0.89% of the stock is currently owned by company insiders.

Institutional Trading of Elanco Animal Health

Several large investors have recently modified their holdings of ELAN. Empowered Funds LLC lifted its holdings in Elanco Animal Health by 35.2% during the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock valued at $166,000 after purchasing an additional 4,121 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after purchasing an additional 2,445,872 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Elanco Animal Health in the first quarter worth about $2,065,000. AQR Capital Management LLC raised its holdings in shares of Elanco Animal Health by 116.4% in the first quarter. AQR Capital Management LLC now owns 524,507 shares of the company’s stock worth $5,332,000 after buying an additional 282,081 shares during the period. Finally, Armistice Capital LLC purchased a new position in Elanco Animal Health during the 1st quarter valued at $138,000. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.